Top

BMC Complementary Medicine and Therapies

Published in:

Open Access 01-12-2018 | Research article

The mutagenic and antimutagenic activity of Sutherlandia frutescens extracts and marker compounds

Authors: Siyabulela S. B. N. Ntuli, Wentzel C. A. Gelderblom, David R. Katerere

Published in: BMC Complementary Medicine and Therapies | Issue 1/2018

Abstract

Background

Sutherlandia frutescens (L.) R. Br is endemic to Southern Africa where it has been traditionally used for cancer and diabetes. In recent times it has been marketed for its reputed (but not proven) anticancer, antidiabetic and anti-HIV properties. Little is known about the mutagenic and antimutagenic potential of extracts and common marker compounds of Sutherlandia frutescens. Therefore this study aimed to investigate the putative efficacy and possible long-term adverse effects of using this herb.

Methods

Ethylacetate (EA) and 50% Methanol (MeOH) extracts were screened for mutagenic and antimutagenic activity using the Ames assay utilising TA97a, TA98, TA100 and TA102 in the presence and absence of metabolic activation. Four compounds, L-arginine, L-canavanine, GABA and D-pinitol known to occur in sutherlandia were also included. The total polyphenolic content of the both extracts was determined using the Folin-Ciocalteau method and FRAP and ABTS were used to determine the anti-oxidant potential of the extracts.

Results

The extracts and the standards did not show any cytotoxicity except in TA97a. The EA extract exhibited antimutagenicity against all the bacterial strains at all concentrations tested. The MeOH extract showed both pro-mutagenic and antimutagenic activities with 2-acetamidofluorene and aflatoxin B1 in the presence of metabolic activation of TA98 and TA100, respectively. All compounds, except L-canavanine exhibited antimutagenic activity against all strains. L-canavanine, on the other hand showed co-mutagenicity with 9-aminoacridine on TA97a, at all test concentrations. The extracts and pure compounds exhibited their antimutagenic activity in a dose response manner. L-arginine and GABA showed an some antimutagenic response. EA extract had three times the total phenolic content (12.56 μg GE / mg) observed in the MeOH extract. There was correlation between total phenolic content, antioxidant potential and antimutagenicity.

Conclusion

Both extracts exhibited a protective effect, with the EA extract exhibiting greater potency. L-canavanine acted as a co-mutagen in a dose response manner without metabolic activation. It is suggested that the EA extract be priotized for future development work as it showed a better risk profile and activity.

Mander M, Mander J, Breen C. Promoting the cultivation of indigenous plants for markets: experiences from KwaZulu-Natal, South Africa. In: RRB L, Temu AB, Melnyk M, et al., editors. Domestication and commercialization of non-timber forest products in agroforestry systems: proceedings of an international conference held in Nairobi, Kenya 19-23 February 1996; 1996. FAO, Rome, 104-109. Non-wood Forest Products no. 9. [http://www.fao.org/docrep/W3735E/W3735E00.htm.

Mander M. Marketing of Indigenous Medicinal Plants in South Africa. A case study in KwaZulu-Natal. Rome: Food and Agricultural Organization of the United Nations; 1998.

van Wyk B-E. An ethnobotanical survey of medicinal plants in the southern Karoo, South Africa. S Afr J Bot. 2008;74:696–704.CrossRef

Elgorashi EE, Taylor JLS, Maes A, van Staden J, De Kimpe N, Verschaeve L. Screening of medicinal plants used in south African traditional medicine for genotoxic effects. Toxicol Lett. 2003;143(2):195–207.CrossRefPubMed

Naidoo V, Seier J. Preclinical safety testing of herbal remedies. In: Katerere DR, Luseba D, editors. Ethnoveterinary botanical medicines for animal health. Boca Raton: CRC Press (Taylor and Francis Group); 2010. p. 69–93.CrossRef

Watt J and Breyer-Brandwijk M. Medicinal and poisonous plants of southern and eastern Africa. 1962. London, Livingstone.

Green M. Method of treating viral infections with amino acid analogues. California: USPO; 1988. p. 600.

Ojewole JAO. Anagelsic, antiinflammatory and hypoglycemic effects of Sutherlandia frutescens R. Br. (variety Incana E. MEY.) [Fabaceae] shoot aqueous extract. Method Find Exp Clin. 2004;26(6):409–16.

van Wyk B-E, Wink M. Medicinal plants of the world, 1^st Ed. Pretoria: Briza Publications; 2004. p7-26, 313, 356, 364, 367, 428. ISBN 1 875093 44 3

10.

Swaffar DS. Combination therapy with 5-fluororacil and L-Canavanine: in vitro and in vivo studies. Anti-Cancer Drugs. 1995;6:586–93.CrossRefPubMed

11.

Bence AK, Adams VR, Crooks PA. L-canavanine as a radio-sensitization agent for human pancreatic cancer cell. Mol Cell Biochem. 2003;244:37–43.CrossRefPubMed

12.

Xaba P and Notten A. Kirstenbosch national botanical garden. 2003: http://www.plantzafrica.com/plantqrs/sutherfrut.htm.

13.

van Wyk B-E, Albrecht A. A review of the taxonomy, ethnobotany, chemistry and pharmacology of Sutherlandia frutescens (Fabaceae). J Ethnopharmacol. 2008;119:620–9.CrossRefPubMed

14.

Chinkwo KA. Sutherlandia frutescens extracts can induce apoptosis in carcinoma cultured cells. J Ethnopharmacol. 2005;98(1-2):163–70.CrossRefPubMed

15.

Katerere DR, Eloff JN. Antibacterial and antioxidant activity of Sutherlandia frutescens (Fabaceae), a reputed anti-HIV/AIDS phytomedicine. Phytother Res. 2005;19(9):779–81.CrossRefPubMed

16.

Tai J, Cheung S, Chan E, Hasman D. In vitro culture studies of Sutherlandia frutescens on human tumor cell lines. J Ethnopharmacol. 2004;93:9–19.CrossRefPubMed

17.

Fu X, Li XC, Smillie TJ, Carvalho P, Mabusela W, Syce J, Johnson Q, Folk W, Avery MA, Khan IA. Cycloartane glycosides from Sutherlandia frutescens. J Nat Prod. 2008;71:1749–53.CrossRefPubMedPubMedCentral

18.

Fu X, Li XC, Wang YH, Avula B, Smillie TJ, Mabusela W, Syce J, Johnson Q, Folk W, Khan IA. Flavonol glycosides from the south African medicinal plant Sutherlandia frutescens. Planta Med. 2010;76(2):178–81.CrossRefPubMed

19.

Sia C. Spotlight on ethnomedicine: usability of Sutherlandia frutescens in the treatment of diabetes. Rev Diabet Stud. 2004;1(3):145–9.CrossRefPubMedPubMedCentral

20.

Bence AK, Worthen DR, Adams VR, Crooks PA. The antiproliferative and immunotoxic effects of L-Canavanine and L-Canaline. Anti-Cancer Drugs. 2002;13(3):313–20.CrossRefPubMed

21.

Rosenthal GA, Reichhart JM, Hoffmann JA. L-Canavanine incorporation into vitellogenin and macromolecular conformation. J Biol Chem. 1989a;264(23):13693–6.PubMed

22.

Ames BN, Profet M, Gold LS. Dietary pesticides (99.99% all natural). Proc Natl Acad Sci U S A. 1990;87(19):7777–81.CrossRefPubMedPubMedCentral

23.

Rosenthal GA, Dahlman DL. Studies of L-Canavanine incorporation into insectan lysozyme. J Biol Chem. 1991;266(24):15684–7.PubMed

24.

Rosenthal GA, Harper L. L-homoarginine studies provide insight into the antimetabolic properties of L-Canavanine. Insect Biochem Mol Biol. 1996;26(4):389–94.CrossRefPubMed

25.

Levy B, Valtier M, de Chillou C, Bollaert PE, Cane D, Mallie JP. Beneficial effects of L-Canavanine, a selective inhibitor of inducible nitric oxide synthase, on lactate metabolism and muscle high energy phosphates during endotoxic shock in rats. Shock. 1999;11(2):98–103.CrossRefPubMed

26.

Jiménez-Jiménez FJ, Molina JA, Gόmez P, Vargas C, de Bustos F, Benito-Leόn J, Tallόn-Barranco A, Ortí-Pareja M, Gasalla T, Arenas J. Neurotransmitter amino acids in cerebrospinal fluid of patients with Alzheimer’s disease. J Neural Transm. 1998;105(2-3):269–77.CrossRefPubMed

27.

Petty F, Kramer GL, Dunnam D, Rush AJ. Plasma GABA in mood disorders. Psychopharmacol Bull. 1990;26(2):157–61.PubMed

28.

Vaiva G, Thomas P, Ducrocq F, Fontaine M, Boss V, Devos P, Rascle C, Cottencin O, Brunet A, Laffargue P, Goudemand M. Low post trauma GABA plasma levels as a predictive factor in the development of acute post traumatic stress disorder. Biol Psychiatry. 2004;55(3):250–4.CrossRefPubMed

29.

Ferrer M, Sanchez-Lamar A, Luis Fuentes J, Llagostera M. Studies on the antimutagenesis of Phyllanthus orbicularis: mechanisms involved against aromatic amines. Mutat Res. 2001;498(1-2):99–105.CrossRefPubMed

30.

Ortega A. A new role for GABA: inhibition of tumor cell migration. Trends Pharmacol Sci. 2003;24:151–4.CrossRefPubMed

31.

Narayanan CR, Joshi DD, Mudjumdar AM, Dhekne VV. Pinitol, a new anti-diabetic compound from the leaves of Bougainvillea spectabilis. Curr Sci. 1987;56(3):139–41.

32.

Ostlund RE and Sherman WR. Pinitol and derivatives thereof for the treatment of metabolic disorders United States patent number 5,8827,896. 1996.

33.

Verschaeve L, Kestens V, Taylor JLS, Elgorashi EE, Maes A, van Puyvelde L, De Kimpe N, van Staden J. Investigation of the antimutagenic effects of selected south African medicinal plant extracts. Toxicol in Vitro. 2004;18(1):29–35.CrossRefPubMed

34.

Popat A, Shear NH, Malkiewicz I, Stewart MJ, Steenkamp V, Thomson S, Neuman MG. The toxicity of Callilepis laureola, a south African traditional herbal medicine. Clin Biochem. 2001;34(3):229–36.CrossRefPubMed

35.

Reid KA, Maes J, Maes A, van Staden J, De Kimpe N, Mulholland DA, Verschaeve L. Evaluation of the mutagenic and antimutagenic effects of south African plants. J Ethnopharmacol. 2006;106(1):44–50.CrossRefPubMed

36.

Vermerris W and Nicholson R. Phenolic compound biochemistry. 2008. Springer Science, USA.

37.

Ames BN, McCann J, Yamasaki E. Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test. Mutat Res. 1975b;31(6):347–64.CrossRefPubMed

38.

Mortelmans K, Zeiger E. The Ames Salmonella/microsome mutagenicity assay. Mutat Res. 2000;455(1-2):29–60.CrossRefPubMed

39.

Maron DM, Ames BN. Revised methods for the Salmonella mutagenicity test. Mutat Res. 1983;113(3-4):173–215.CrossRefPubMed

40.

Vedmaurthy RB, Padmanabhan S, Vijayan M, Jamal ZA, Kunjumman J, Narayanan ML. Compatibility of different solvents with Salmonella typhimurium mutant strains in bacterial reverse mutation assay. Int J Pharm Pharm Sci. 2012;4:283–4.

41.

Snijman PW, Swanevelder S, Joubert E, Green IR, Gelderblom WCA. The antimutagenic activity of the major flavonoids of rooibos (Aspalathus linearis): some dose-response effects on mutagen activation-flavonoid interactions. Mutat Res. 2007;631(2):111–23.CrossRefPubMed

42.

Singleton VL, Orthofer R, Lamuela-Raventos RM. Analysis of total phenols and other antioxidants by means of Folin-Ciocalteau reagent. Methods Enzymol. 1999;299:152–78.CrossRef

43.

Lee JH, Renita M, Fioritto RJ, Martin SST, Schwartz SJ, Vodovotz Y. Isoflavone characterization and antioxidant activity of Ohio soybeans. J Agric Food Chem. 2004;52:2647–51.CrossRefPubMed

44.

Hatami T, Emami SA, Miraghaee SS, Moarrab M. Total phenolic content and antioxidant activity of different extracts and fractions from aerial parts of Artemisia biennis Willd. Iran J Pharm Res. 2014;13(2):551–8.PubMedPubMedCentral

45.

Benzie IFF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: the FRAP assay. Anal Biochem. 1996;239:70–6.CrossRefPubMed

46.

Re R, Pellegrini N, Proteggente A, Pannala A, Yang M, Rice-Evans C. Antioxidant activity applying an improved ABTS radical cation decolorization assay. Free Radic Biol Med. 1999;26(9/10):1231–7.CrossRefPubMed

47.

Gomes-Carneiro MR, Dias DM, Paumgartten FJ. Study on the mutagenicity and antimutagenicity of β-ionone in the Salmonella/microsome assay. Food Chem Toxicol. 2006;44(4):522–7.CrossRefPubMed

48.

Kaleeswaran S, Sriram P, Prabhu D, Chinnathambi, Vijaykumar C, Mathuram LN. Anti- and pro-mutagenic effects of silymarin in the Ames bacterial reverse mutation assay. Phytother Res. 2009;23(10):1378–84.CrossRefPubMed

49.

Park K-Y, Jung G-O, et al. Antimutagenic activity of flavonoids from the heartwood of Rhus verniciflua. J Ethnopharmacol. 2004;90(1):73–9.CrossRefPubMed

50.

Edenharder R, Rauscher R, Platt KL. The inhibition by flavonoids of 2-amino-3-methylimidazo[4,5-f]quinoline metabolic activation to a mutagen: a structure-activity relationship study. Mutat Res. 1997;379(1):21–32.CrossRefPubMed

51.

Zeiger E. Illusions of safety: antimutagens can be mutagens, and anticarcinogens can be carcinogens. Mutat Res. 2003;543:191–4.CrossRefPubMed

52.

Bhattacharya S. Natural antimutagens: a review. Res J Med Plant. 2011;5(2):116–26.CrossRef

53.

Thomson S. Canavanine toxicity: is Sutherlandia a healthy herb or potent(ial) poison? HIV positives and AIDS sufferers beware: the remedy may be worse than the alleged disease. Knysna: Geaia Research Institute; 2002.

54.

Thompson S. Sutherlandia “fails” safety test. Sutherlandia Immuno pseudo-science. http://www.gaiaresearch.co.za/sutherlandia.html: Gaia Research Institute; 2003.

55.

Cotelle N. Role of flavonoids in oxidative stress. Curr Top Med Chem. 2001;1(6):569–90.CrossRefPubMed

56.

Odontuya G, Hoult JR, Houghton PJ. Structure-activity relationship for antiinflammatory effect of luteolin and its derived glycosides. Phytother Res. 2005;19(9):782–6.CrossRefPubMed

57.

Negi PS, Jayaprakasha GK, Jena BS. Antioxidant and antimutagenic activities of pomegranate peel extracts. Food Chem. 2003;80(3):393–7.CrossRef

58.

Calabrese EJ. Biphasic dose responses in biology, toxicology and medicine: accounting for their generalizability and quantitative features. Environ Pollut. 2013;182:452–60.CrossRefPubMed

59.

van der Merwe JD, Joubert E, Richards ES, Manley M, Snijman PW, Marnewick JL, Gelderblom WCA. A comparative study on the antimutagenic properties of aqueous extracts of Aspalathus linearis (rooibos), different Cyclopia spp. (honeybush) and Camellia sinensis teas. Mut Res. 2006;611(1-2):42–53.CrossRef

60.

Dashwood RH. Modulation of heterocyclic amine-induced mutagenicity and carcinogenicity: an ‘A-to-Z’ guide to chemopreventive agents, promoters, and transgenic models. Mut Res. 2002;511(2):89–112.CrossRef

61.

Rosenthal GA. The biochemical basis for the deleterious effects of L-canavanine. Phytochemistry. 1991;30(4):1055–8.CrossRef

62.

Syed DN, Khan N, Afaq F, Mukhtar H. Chemoprevention of prostate Cancer through dietary agents: progress and promise. Cancer Epidemiol Biomark Prev. 2007;16(11):2193–203.CrossRef

63.

Zeiger E. Mutagens that are not carcinogens: faulty theory or faulty tests? Mut Res. 2001;492(1-2):29–38.CrossRef

Title: The mutagenic and antimutagenic activity of Sutherlandia frutescens extracts and marker compounds
Authors: Siyabulela S. B. N. Ntuli
Wentzel C. A. Gelderblom
David R. Katerere
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: BMC Complementary Medicine and Therapies / Issue 1/2018
Electronic ISSN: 2662-7671
DOI: https://doi.org/10.1186/s12906-018-2159-z

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

The mutagenic and antimutagenic activity of Sutherlandia frutescens extracts and marker compounds

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Chebulinic acid derived from triphala is a promising antitumour agent in human colorectal carcinoma cell lines

Rhaponticum acaule (L) DC essential oil: chemical composition, in vitro antioxidant and enzyme inhibition properties

Antituberculosis activity, phytochemical identification of Costus speciosus (J. Koenig) Sm., Cymbopogon citratus (DC. Ex Nees) Stapf., and Tabernaemontana coronaria (L.) Willd. and their effects on the growth kinetics and cellular integrity of Mycobacterium tuberculosis H37Rv

Artemisia Capillaris leaves inhibit cell proliferation and induce apoptosis in hepatocellular carcinoma

4-Acetylantroquinonol B inhibits lipopolysaccharide-induced cytokine release and alleviates sepsis through of MAPK and NFκB suppression

The development of a survey instrument to measure the barriers to the conduct and application of research in complementary and alternative medicine: a Delphi study